Alkem Laboratories' Net Profit Up by 22.3% in FY25; Declares Rs. 8 Per Share Final Dividend
By Ankur Chandra | Updated at: May 31, 2025 10:41 PM IST
Alkem Laboratories Ltd, a leading Indian pharmaceutical company, announced its audited financial results for the quarter and fiscal year ended March 31, 2025. The company reported robust year-on-year growth in both its standalone and consolidated performance, supported by higher revenues and disciplined cost management. The board also declared a substantial final dividend.
Key Financial Highlights (₹ in million)
| Particulars | FY25 | FY24 | YoY Growth |
|---|---|---|---|
| Consolidated Revenue | 129,645.2 | 126,675.8 | 2.3% |
| Consolidated Net Profit | 22,153.8 | 18,114.6 | 22.3% |
| Standalone Revenue | 88,134.4 | 79,638.5 | 10.6% |
| Standalone Net Profit | 22,808.9 | 17,471.5 | 30.5% |
| EPS (Consolidated, Basic) | ₹181.11 | ₹150.19 | – |
| EPS (Standalone, Basic) | ₹190.77 | ₹146.13 | – |
Dividend: The company declared a final dividend of ₹8 per equity share (face value ₹2), in addition to an interim dividend of ₹37 per share already paid in February 2025, taking the total FY25 payout to ₹45 per share.
Segment Performance & Strategic Initiatives
- Business Structure: The company operates a single business segment Pharmaceuticals with global presence through 30+ subsidiaries.
- Discontinued Operations: The company has initiated the transfer of its Generic Business Undertaking to its wholly owned arm, Alkem Wellness Ltd, on a slump sale basis. This unit is now classified under discontinued operations, contributing ₹1,911.7 million in profit during FY25.
- Facility Divestment: Alkem identified its Indore manufacturing facility for divestment, and related assets have been classified as ‘held for sale’.
Balance Sheet Snapshot (as of March 31, 2025)
| Particulars | Consolidated (₹ mn) | Standalone (₹ mn) |
|---|---|---|
| Total Assets | 176,911.0 | 155,956.0 |
| Total Equity | 124,336.3 | 123,218.3 |
| Cash & Cash Equivalents | 3,041.4 | 749.2 |
| Investments (non-current + current) | 18,131.2 | 13,676.3 |
Corporate Announcements
- Board Appointments:
- Mr. Ranjal Laxmana Shenoy and Ms. Neela Bhattacherjee were appointed as Independent Directors for a term of 5 years starting July 13, 2025.
- Secretarial Auditor: M/s. Manish Ghia & Associates appointed as Secretarial Auditors for FY26–FY30.
- AGM Schedule: The 51st AGM is scheduled for August 25, 2025; record date for dividend is August 8, 2025.
Management Commentary
B.N. Singh, Executive Chairman, stated: “FY25 was a landmark year where we not only achieved consistent growth across geographies but also strengthened our focus through strategic restructuring. The dividend shows our continued commitment to value creation for shareholders.”
Strategic Outlook
Given its strong domestic portfolio, aggressive foray into regulated markets and sustained focus on operational efficiency, Alkem is set for consistent healthy growth. The generics business divestment and manufacturing asset optimization are also consistent with its forward-looking global strategy.
About Alkem Laboratories Ltd:
Founded in 1973, Alkem is a top-tier Indian pharma player engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products, with a strong footprint in the U.S., India, and other international markets. The company has a consistent track record of profitability and dividend distribution.
Dividend History Snapshot (₹ per share):
| FY | Interim | Final | Total |
|---|---|---|---|
| FY25 | 37 | 8 | 45 |
| FY24 | 20 | 10 | 30 |
| FY23 | 15 | 10 | 25 |
Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. Please read the offer documents carefully before investing. Investments are subject to market risks and other risks. There is no guarantee of the actual returns that will be given.
REF: https://nsearchives.nseindia.com/corporate/ALKEM_29052025135437_AlkemOutcomeofBoardMeeting29052025.pdf
